ALFA Finder| Revenue growth | 18% YoY growth in Q1FY27. |
|---|---|
| Margins | Adjusted EBITDA margin improved to 13.6% from 12.8%. |
| Demand visibility | Strong CDMO demand; expanding customer base to 926. |
| Management confidence | High; citing 14 consecutive quarters of growth. |
Growth
Generic Formulations CDMO grew 29% YoY; Exports surged 79%. Trade Generics declined 32% due to codeine product discontinuation.
Outlook
Plant-6 commercialization on track for H1FY27. Capex of ₹73 Cr in FY26 focused on OSD capacity expansion.
Risks
Trade Generics vertical faced headwinds from product discontinuation; non-cash ESOP expenses impacted reported margins.
Last quarter's promises, checked
Delivered
- Plant 6 commercialization by H1 FY27 → On track (= BEAT)
- Maintain ROCE/ROE above 25% → Sustained above 25% (= BEAT)
- Revenue growth outperforming IPM volume → 18% vs 3.4% (= BEAT)
Partly delivered
- Injectables scaling → Catching up but with earlier timeline lag (= PARTIAL)
Missed
- Trade Generics growth → -32% decline due to codeine exit (= MISS)
Investor Presentation filed with NSE, NSE: WINDLAS. Summary written with AI assistance from the document.
Windlas Biotech Ltd: key numbers
- Share price
- ₹998.85
- Market cap
- ₹2,096 Cr
- Revenue (annual)
- ₹904.1 Cr
- Net profit (annual)
- ₹66.44 Cr
- P/E (TTM)
- 31.4×Sector 43.8×
- Promoter holding
- 63.31%+0.00% QoQ
- FII holding
- 2.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Windlas Biotech Ltd
All →Windlas Biotech Management Change
Windlass Biotech reports Mr. Ashok Kumar Windlass ceased as Executive Director, resigning for succession planning, effective 5 November 2026. He moves to Founder President, and Hitesh Windlass becomes Managing Director.
Windlas Biotech Results Update
Windlas Biotech reported H1 FY27 revenue of Rs 512 crore, up 18% YoY. Adjusted PAT rose 33% to Rs 50 crore for the half year.
Windlas Biotech Investor Presentation: Key Takeaways
H1FY27 revenue Rs 512 Cr (+18%), adj. PAT Rs 50 Cr (+33%, 9.7% margin); reported PAT flat at Rs 36 Cr on ESOP charges. CDMO-led growth; Plant-6 commercialised.
Windlas Biotech Q2 FY27 Results: Net Profit ₹18.1 Cr, Up 1.7% YoY
Windlas Biotech Ltd reported revenue from operations of ₹263.9 Cr (+18.7% YoY) and net profit of ₹18.1 Cr (+1.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹18.1 Cr · +1.7% YoY
Windlas Biotech Adverse Business Impact
Windlas Biotech disclosed a cyber security incident on 30 October 2026. It states no material impact on core operations, finances or business continuity.
Windlas Biotech Board Meeting Date
Windlas Biotech intimated that its Board meeting is scheduled for 5 November 2026 to consider unaudited standalone results for Q1 FY27. No monetary figure is disclosed in this advance notice.